Intrexon Depended on 1 Customer for 58% of First-Half 2017 Revenue Growth

The single biggest problem facing engineered biology conglomerate Intrexon (NYSE: XON) heading into the second quarter of 2017 was its dependency on small- and micro-cap companies for a significant portion of its total revenue and nearly all of its revenue growth. These companies often fail -- several that formerly accounted for large payments already have -- which puts the synthetic biology stock on shaky ground.

After Intrexon reported second-quarter 2017 earnings, it's clear that investors are still being forced to go along with the company's risky revenue machine. An astounding 58% of all first-half 2017 revenue growth over the year-ago period came from just one customer, Ziopharm (NASDAQ: ZIOP). Meanwhile, start-ups created for and by Intrexon accounted for another 54% of revenue growth during the periods.

Your math is correct: These two sources add up to 112% of total revenue growth, which means they more than made up for shrinking business elsewhere.

Source: Fool.com